Correlation of hENT1 expression with response and survival in non-small cell lung cancer patients treated with gemcitabine-containing chemotherapy

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22032-e22032
Author(s):  
T. Oguri ◽  
H. Achiwa ◽  
H. Ozasa ◽  
M. Nakao ◽  
T. Uemura ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Immunohistochemical Analysis ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Positive Staining ◽  
Prognostic Impact ◽  
Nucleoside Transporter ◽  
Exact Test ◽  
Lung Cancer Patients ◽  
Third Line

e22032 Background: The most active gemcitabine uptake has been found via the human equilibrative nucleoside transporter 1 (hENT1). This study was to explore the prognostic impact of the hENT1 on response and survival in Non-small lung cancer (NSCLC) patients treated with gemcitabine-containing chemotherapy. Methods: We developed polyclonal antibody for hENT1. Then we stained hENT1 expression by immunohistochemical analysis in 24 biopsy samples of NSCLC which was formaline-fixed, paraffin- embedded tissues. We were treated with gemcitabine alone or gemcitabine-containing chemotherapy until third-line regimen. Results: They comprised 16 males and 8 females with a median age of 63 years (range 45–82 years). Seventeen patients had adenocarcinomas, six had squamous-cell carcinomas, and one had a large-cell carcinoma. All patients were treated with gemcitabine- containing chemotherapy, with 9, 12, and 3 patients receiving this as a first-, second-, and third-line therapy, respectively. The hENT1-positive staining in NSCLC samples was significantly associated with response to gemcitabine-containing chemotherapy (Fisher's exact test, P<0.05). Responses to gemcitabine-containing chemotherapy were evident in none of the seven patients with no hENT1 expression. Further 3 years survival differed by hENT1 staining: 714 days for hENT1-positive, 316 days for hENT1-negative (HR 2.86; 95%CI 1.13–15.16, P<0.05). Conclusions: While there are some determinants for gemcitabine sensitivity, hENT1 expression may be a predictive maker for the response and survival to gemcitabine-containing chemotherapy in NSCLC. No significant financial relationships to disclose.

scholarly journals Bacteriological and Cytological study For bronchial washes from lung cancer patients

2011 ◽  
Vol 8 (1) ◽  
pp. 406-415
Author(s):  
Baghdad Science Journal
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Cytological Study ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Biochemical Tests ◽  
Dominant Type ◽  
Lung Cancer Patients ◽  
Esherichia Coli ◽  
Bronchial Wash

The study included the collection of 75 bronchial wash samples from patients suspected to have lung cancer. These samples were subjected to a diagnostic cytological study to detect the dominant type of lung cancer. It was noticed that 33 patients proved to have a lung cancer out of 75 (44%) of these, 19 cases (57.6%)were diagnosed having Squamus cell carcinoma,7cases (21.21%) showed Adenocarcinoma ,6 cases (18.18%) were having small cell carcinoma while only one case (3.03%)was large cell carcinoma .Nearly 70% of cases were correlated with smokers .Bacteria were isolated from 53 patients in which 33 isolates were associated with the cancer cases while 20 of them from non infected patients. By using different morphological ,biochemical tests followed by api20 ,the bacterial isolates correlated with cancer were diagnosed and were characterized as 12 isolates (36.36%) of Pseudomonas aeruginosa ,6 isolates (18.18%) were Klebsiella pneumoniae ,Pseudomonas fluorescence and Esherichia coli for each while only 3 isolates (9.09%)of Acinetobacter baumannii were isolated. Some of bacterial virulence factors were determined in which,24 isolates (72.7%) were capable of agglutinating red blood cells, 16 isolates (48.5%) had the ability to adhere to epithelial cells , in addition ,15 isolates (45.5%) proved to have capsule and 24 isolates(72.7%) gave a positive results in heamolysin test beside ,25 isolates (75.8%) were ß –Lactamase producers. The isolates were highly resisted Ampicillin, Amoxicillin and Cefotaxime while they were inhibited by low concentrations of Ciprofloxacin and Cefepime the 4th generation cephalosporins.

Gender difference in susceptibility to smoking in Korean lung cancer patients having smoking habits

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 17158-17158
Author(s):  
J. Ryu ◽  
H. Lee ◽  
J. Cho ◽  
S. Kwak ◽  
H. Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Forced Expiratory Volume ◽  
Smoking Habits ◽  
Carcinogenic Effect ◽  
Lung Cancer Patients ◽  
Susceptibility To Smoking

17158 Background: There were some controversies whether women were more or less susceptible to the carcinogenic effect of cigarette smoke and the decline of forced expiratory volume in 1 second (FEV1) to pack-years compared to men. Methods: In this study, we included all lung cancer patients having smoking habits who was histologically diagnosed and performed pulmonary function testing at the time of diagnosis from September 2001 through December 2005. We estimated individual susceptibility to smoking using a formula (SI, susceptibility index) of (100% predicted FEV1)/pack-years. Results: Of 858 lung cancer patients, sex ratio (M/F) was 14.6 (803/55). Past smokers were in 236 (29.3%) for men, 11 (20.0%) for women. Most common hsitologic type was squamous cell carcinoma (477), adenocarcinoma (191), small cell carcinoma (147), adenosquamous cell carcinoma (14), large cell carcinoma (14), NSCLC cell type not specified (15). Pack-years were 41.3 ± 18.9 for men, 29.2 ± 20.4 for women (P = 0.000). FEV1 % was 78.7 ± 23.3 for men, 79.4 ± 22.9 for women (P = 0.832). As for SI, there were no differences between men (0.65 ± 1.1) and women (0.72 ± 1.6) (P = 0.688). Conclusions: Although lung cancer women having smoking habits showed lower pack-years, there were no gender differences in terms of FEV1 decline to cigarette smoking. No significant financial relationships to disclose.

scholarly journals A Case Report of Incomplete Carney Complex With SMARCA4-Deficient Thoracic Sarcoma: Implications for the SLC7Aaa and ARID1A Expression

2021 ◽  
Author(s):  
yusuke kito ◽  
Keisuke Kawashima ◽  
Chiemi Saigo ◽  
Masayoshi Hasegawa ◽  
Shusuke Nomura ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Epithelioid Sarcoma ◽  
Immunohistochemical Analysis ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Large Mass ◽  
Soft Tissue Tumors ◽  
Genetic Alterations ◽  
Undifferentiated Carcinoma ◽  
Carney Complex

Abstract Background: SWI/SNF-related, matrix-associated, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member (SMARCA4)-deficient thoracic sarcoma (SMARCA4-DTS) is a rare disease that has recently been described as an entity. It is characterized by an aggressive clinical course and specific genetic alterations. As an immunohistological feature, the tumors are deficient in SMARCA4 and SMARCA2 and express the sex-determining region Y-box 2 (SOX2). In contrast, Carney’s triad is a syndrome that combines three rare soft tissue tumors: gastric leiomyosarcoma, pulmonary chondroma, and extra-adrenal paraganglioma, of which at least two are required for diagnosis. Both diseases are valuable case, and there have been no previous reports of their coexistence.Case presentation: A 43-year-old man visited our hospital because of respiratory distress. Computed tomography revealed a large mass measuring 55 mm in the upper lobe of his right lung and front mediastinum, with metastases in the surrounding lymph nodes. Needle biopsy was performed for diagnosis, and histological examination of the samples revealed monotonous epithelioid-like cells with loose binding and sheet-form proliferation. The tumor cells had distinct nuclei, with rhabdoid-kile cells in some locations. Immunohistochemical analysis revealed that the tumor cells were positive for SOX2, CD34, and p53 and negative for SMARCA4 and SMARCA2. The patient died 6 months after admission without any treatment. Autopsy revealed ganglioneuroma and enchondroma, suggesting an incomplete Carney complex.Conclusion: SMARCA4-DTS is a rare and recently established disease. While it is difficult to siagnose, it is necessary to distinguish undifferentiated carcinoma, large cell carcinoma, Ewing sarcoma, epithelioid sarcoma, etc. when diagnosing tumors involving the mediastinum, In addition, case with both an incomplete Carney complex and SMARCA4-DTS are very rare. We discuss and report about SMARCA4-DTS by examining the expression of AT-rich interactive domain-containing protein 1A and solute carrier family 7 member 11.

scholarly journals Infections and Immunotherapy in Lung Cancer: A Bad Relationship?

2020 ◽  
Vol 22 (1) ◽  
pp. 42
Author(s):  
Lorenzo Belluomini ◽  
Alberto Caldart ◽  
Alice Avancini ◽  
Alessandra Dodi ◽  
Ilaria Trestini ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Infectious Diseases ◽  
Cancer Patients ◽  
Bacterial Infections ◽  
Viral Infections ◽  
Checkpoint Inhibitors ◽  
Current Evidence ◽  
Human Immune Deficiency Virus ◽  
Prognostic Impact ◽  
Lung Cancer Patients

Infectious diseases represent a relevant issue in lung cancer patients. Bacterial and viral infections might influence the patients’ prognosis, both directly affecting the immune system and indirectly impairing the outcome of anticancer treatments, mainly immunotherapy. In this analysis, we aimed to review the current evidence in order to clarify the complex correlation between infections and lung cancer. In detail, we mainly explored the potential impact on immunotherapy outcome/safety of (1) bacterial infections, with a detailed focus on antibiotics; and (2) viral infections, discriminating among (a) human immune-deficiency virus (HIV), (b) hepatitis B/C virus (HBV-HCV), and (c) Sars-Cov-2. A series of studies suggested the prognostic impact of antibiotic therapy administration, timing, and exposure ratio in patients treated with immune checkpoint inhibitors, probably through an antibiotic-related microbiota dysbiosis. Although cancer patients with HIV, HBV, and HCV were usually excluded from clinical trials evaluating immunotherapy, some retrospective and prospective trials performed in these patient subgroups reported similar results compared to those described in not-infected patients, with a favorable safety profile. Moreover, patients with thoracic cancers are particularly at risk of COVID-19 severe outcomes and mortality. Few reports speculated about the prognostic implications of anticancer therapy, including immunotherapy, in lung cancer patients with concomitant Sars-Cov-2 infection, showing, to date, inconsistent results. The correlation between infectious diseases and immunotherapy remains to be further explored and clarified in the context of dedicated trials. In clinical practice, the accurate and prompt multidisciplinary management of lung cancer patients with infections should be encouraged in order to select the best treatment options for these patients, avoiding unexpected toxicities, while maintaining the anticancer effect.

Sign in / Sign up

Export Citation Format

Share Document